Triple Negative Breast Cancer (TNBC)Phase 1VITAL-TNBCNCT07652242
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
A Phase 1 study testing ITI-5000 mRNA Vaccine, Pembrolizumab and Olaparib in people with Triple Negative Breast Cancer (TNBC), run by Immunomic Therapeutics, Inc. at 2 sites in United States.
Trial summary
This study tests an investigational cancer vaccine called ITI-5000 in people who have completed standard treatment for early-stage triple-negative breast cancer (TNBC). ITI-5000 is a self-amplifying RNA (saRNA) vaccine that instructs the immune system to recognize and attack cancer cells expressing two proteins found… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Triple Negative Breast Cancer (TNBC)
- What is being tested?
- ITI-5000 mRNA Vaccine, Pembrolizumab and Olaparib
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 2 sitesUnited States
- Study dates
- 14 Jul 2026to Aug 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Applicable to Part A only. Participants must have completed adjuvant pembrolizumab if they were receiving it before enrolling in the study.
- Applicable to Cohort 3A and Part B only. Participant must have received neoadjuvant chemotherapy with pembrolizumab, then undergone definitive surgery. At the time of surgery, participant must not have achieved pCR.
- Applicable to Part B only. Participant is currently receiving or is planned to receive standard of care adjuvant therapy, including pembrolizumab in combination with capecitabine or olaparib in accordance with the FDA-approved label, with ≥3 cycles remaining if receiving 200mg Q3W or ≥2 cycles remaining if receiving 400 mg Q6W at the time of first ITI-5000 dose.
- Adults aged 18 years or over.
- Participants provided a signed and dated ICF.
- Participant agrees not to receive any routine vaccinations until at least 30 days after receiving the last study vaccine.
Show all 21Show fewer
- TNBC diagnosed as pathologic stage 2-3 according to American Joint Committee on Cancer (AJCC) and confirmed by histological examination, e.g., negative for HER2 as defined by ASCO CAP 2023 guidelines. ER and PgR receptor negative by immunohistochemistry. Participants with BRCA mutations will be allowed.
- Concurrent endocrine therapy (e.g., tamoxifen, aromatase inhibitors, ovarian suppression) is not permitted during study participation. Concurrent CDK4/6 inhibitors (ribociclib/abemaciclib) are not allowed.
- Applicable to Part A only. Participants with more than 4 weeks since last active therapy (chemotherapy, radiation therapy, or surgery) and 36 months or less following definitive surgery, based on the period of highest risk for recurrence in participants with stages 2-3 TNBC.
- Applicable to Part A only. Participants completed all planned previous cancer treatment (e.g., chemotherapy, radiation, therapy, surgery).
- Participant's ECOG performance status is 0 or 1.
- Participant had no significant ischemic heart disease or myocardial infarction within 3 months before vaccination #1 and has adequate cardiac function during eligibility evaluation, as evidenced by QTc of ≤470 msec for females or ≤450 msec for males assessed by the Fridericia method (QTcF) and evidenced by the average of measurements from triplicate ECGs at the screening visit.
- The eligibility of participants with ventricular pacemakers for whom the QT interval may not be accurately measurable will be determined on a case-by-case basis by the sponsor in consultation with the medical monitor.
- Participant has an adequate organ function, as evidenced by the following tests conducted within 7 days before enrollment:
- Hematology examination (excluding blood transfusion or use of hematopoietic stimulating agents for correction):
- 1. Hemoglobin ≥8.0 g/L 2. Absolute neutrophil count (ANC) ≥1.0 × 109/L 3. Platelet count ≥100 × 109/L ii. Serum biochemistry examination (excluding recent blood transfusion or albumin administration):
- 1. Alanine aminotransferase and AST ≤1.5 times the ULN 2. Alkaline phosphatase ≤2.5 ULN 3. Total bilirubin ≤ 1.5 ULN 4. Serum creatinine ≤1.5 ULN, with creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula) 13. Women of childbearing potential have a negative serum pregnancy test within 3 days before vaccination #1, and they and their partners agree to use highly effective methods of contraception during the study and for 6 months after the last administration of the study drug.
- NOTE: A woman is considered of non-childbearing potential if she has had a documented bilateral oophorectomy, tubal ligation, or hysterectomy, or if she is postmenopausal, defined as ≥12 months of spontaneous amenorrhea without an alternative medical cause (with serum FSH confirmation if <55 years old). 14. Participant is able to attend the required study visits and follow-up as required by this protocol.
- 15. Participant is able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines prior to study registration.
- 16. Participant agrees not to use alternative therapies from the time of informed consent through 30 days following vaccination #3. Participants may be asked to complete a "wash out" period before vaccination #1 at the principal investigator's discretion to ensure the absence of all alternative therapies.
- NOTE: "Alternative therapies" refer to non-prescription or non-standard medical interventions used with the intent to treat or prevent cancer or its symptoms, including but not limited to herbal remedies, high-dose dietary supplements marketed for therapeutic benefit, homeopathic preparations, or naturopathic treatments. Routine vitamins, minerals, or supportive care measures not expected to affect immune function may be continued at the investigator's discretion.
Who cannot join
- Applicable to Part B only. Participant discontinued prior treatment with an ICI due to irAEs.
- Participant underwent major surgery within 4 weeks before the planned day of vaccination #1 or received any other investigational drug or device within 4 weeks or 5 half-lives of that agent (whichever is shorter) before the planned day of Vaccination #1.
- Applicable to Part A only. Participant received cancer-directed therapy (chemotherapy, radiotherapy, biologic or immunotherapy, etc.) within 4 weeks or 5 half-lives of that agent (whichever is shorter) before the planned day of Vaccination #1. ii. Applicable to Part B only. Participants who received any PD-1 or PD-L1 inhibitor other than pembrolizumab will be excluded unless they have completed a washout period of ≥ 4 weeks or 5 half-lives of that agent (whichever is shorter) before Vaccination #1.
- Participant has toxicities due to prior immunotherapy. For the participant to be eligible, these toxicities must either have returned to ≤ Grade 1 or baseline or been deemed irreversible and in the opinion of the investigator not worsened by immunotherapy (e.g., ICI-endocrinopathies). Participants with any cardiac toxicities (regardless of the grade, etc.) will be excluded.
- Participant has toxicities due to prior chemotherapy that have not been resolved or considered stable and clinically manageable (e.g., neuropathies). Participants with any cardiac toxicities will be excluded.
- Participant has a significant medical illness, underlying health condition, or abnormal laboratory finding that, in the investigator's opinion, would increase the risk of participating in the study.
Show all 25Show fewer
- Participants with an active autoimmune disease requiring immunosuppressive treatment within the last year (excluding irAEs), such as chronic prolonged systemic corticosteroid use (defined as corticosteroid use lasting one month or more).
- Female participants who are trying to conceive, are pregnant, or lactating.
- A positive serum pregnancy test at screening and/ or a positive human chorionic gonadotropin (hCG) urine test at baseline in women of childbearing potential.
- Participant concurrently participates in any other interventional clinical trial.
- Participant has known allergies to any of the components of the study vaccine.
- Participant has a history of anaphylaxis requiring medical intervention (including severe reactions to other mRNA vaccines, such as those against SARS-COV-2, etc.).
- Participant has a history of stroke, transient ischemic attack, unstable angina, or myocardial infarction within 3 months prior to the first dose of study treatment.
- Participant has a history of myocarditis or pericarditis.
- Participant has symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification), clinically significant cardiac arrhythmia, or a known left ventricular ejection fraction <45%.
- Participant has a history of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) or requires the use during study participation of concomitant medications known or suspected to prolong the QT/QTc interval, with the exception of drugs with low risk of QT/QTc prolongation that are used as standard premedication (e.g., diphenhydramine, famotidine, ondansetron).
- Participant received an mRNA or a live virus vaccine within 28 days of the planned vaccination #1. Flu and COVID vaccinations/boosters are also prohibited within 28 days before the planned day of vaccination #1. Vaccines that do not contain live virus are permitted.
- Participant has prior malignancy, except for the following:
- adequately treated basal-cell or squamous-cell skin cancer, ii. in situ cervical cancer, iii. any other cancer from which the participant has been disease-free for at least 3 years.
- Participant has a history of organ transplant requiring immunosuppression. Participants with unstable human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) are not eligible.
- Stable and well controlled HIV/AIDS participants on retroviral therapy, defined as those with no dose change within 4 weeks before the planned day of vaccination #1 and no anticipated dose change, are eligible.
- Participant with known active hepatitis B or C are not eligible. Active hepatitis B is defined as a known positive hepatitis B surface antigen (HBsAg) result. Active hepatitis C is defined by a known positive hepatitis C antibody result and known quantitative hepatitis C virus RNA results greater than the lower limits of detection of the assay.
- Participants with a history of infection with hepatitis B virus or HCV may enroll if the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.
- Participant was assessed by the investigator as being unable or unwilling to comply with the requirements of the treatment schedule and study procedures for any reason.
- Participant has a contraindication to IM injections or blood draws.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
START Midwest
Grand Rapids, Michigan, 49546
Dr. Lakhani, MD, hopeteam@startresearch.com
Nehal Lakhani, MD
- Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
Dr. Sarah Premji, MD, SCRI.DDUreferrals@scri.com
Sarah Premji, MD
About this study
Official title: A Phase 1, Multicenter, Open-label, First-in-Human Study of ITI-5000 (Self-Amplifying RNA Vaccine) Alone and in Combination With Standard of Care Adjuvant Therapy in Participants With Stage II-III Triple-Negative Breast Cancer (TNBC)
This study tests an investigational cancer vaccine called ITI-5000 in people who have completed standard treatment for early-stage triple-negative breast cancer (TNBC).
ITI-5000 is a self-amplifying RNA (saRNA) vaccine that instructs the immune system to recognize and attack cancer cells expressing two proteins found on TNBC cells-HERV-K and CT83-fused with a molecule called LAMP-1 that helps the immune system respond more strongly. The vaccine is delivered inside lipid nanoparticles (LNPs), similar to other approved mRNA vaccines.
Read more
The study has two parts:
- Part A: Participants receive ITI-5000 alone at one of two dose levels (1 µg or 10 µg), given as an injection into the upper arm muscle every 28 days for 3 doses total. The goal is to find the safest dose.
- Part B: Participants receive ITI-5000 at the best dose identified in Part A, combined with the following approved immunotherapy drugs pembrolizumab (Keytruda) and either olaparib or capecitabine.
Read the detailed description
This will be a phase 1, FIH, multicenter, open-label, two-part, ascending dose study to evaluate the safety, tolerability, and immune response of the ITI-5000 vaccine in adult participants with TNBC (stage 2-3). The study will be divided into 2 parts: in Part A, participants will receive the ITI-5000 vaccine as a single agent in the post-adjuvant setting, and in Part B, participants will receive the ITI-5000 vaccine in combination with standard of care adjuvant therapy.
Part A will be divided into 2 dose level cohorts - Cohort 1A conducted at the dose of 1 μg (low dose) per vaccination and Cohort 2A conducted at the dose of 10 μg (high dose) per vaccination. In Part A, three vaccinations of ITI-5000 will be administered with a 28-day interval.
The first 3-6 participants will be enrolled sequentially, with the first participant designated as a sentinel participant who will be monitored for 28 days after receiving the first ITI-5000 vaccination before subsequent participants are enrolled. If 0/3 participants experience a DLT, Cohort 2A may proceed. If 1/3 of the participants experience a DLT, the cohort will expand to include 3 additional participants (total of 6). If ≥2/6 participants experience a DLT, the dose will be considered not tolerable, and the cohort will be stopped.
At the conclusion of each cohort, the safety review committee (SRC) will review safety signals and determine a rationale for dose escalation, de-escalation, or potential intermediate doses to be evaluated. The SRC will also determine the dose to be evaluated in Cohort 3A and Part B.
The MTD will be evaluated in Cohort 3A which will enroll up to 15 participants who did not achieve pathological complete response (pCR) following neoadjuvant therapy. This expansion will allow further assessment of safety and immunogenicity in a participant population that is at high risk of disease recurrence.
Part B will evaluate the MTD of ITI-5000 in combination with standard of care (SOC) adjuvant therapy among participants who did not achieve a pathological complete response (pCR) following neoadjuvant therapy.
A safety lead-in group comprising 3 participants will be enrolled at the beginning of Cohort 1B and 2B to assess the safety of the combination treatment. Unlike Part A, no sentinel participant will be required, as the safety of ITI-5000 alone will already have been established in Part A. The safety lead-in will provide an early evaluation of the tolerability of the combination regimen before enrolling additional participants.
Cohort 1B will enroll up to 20 participants with BRCA1/2 mutation who did not achieve pathological complete response (pCR) following neoadjuvant therapy. Three doses of ITI-5000 will be administered in the adjuvant setting with a 21-day interval in combination with standard of care (pembrolizumab 200 mg Q3 weeks or 400 mg Q6 weeks and olaparib as per FDA approved label and currently accepted guidelines).
Cohort 2B will enroll up to 20 participants with wild-type BRCA1/2 who did not achieve pCR following neoadjuvant therapy. Three doses of ITI-5000 will be administered in the adjuvant setting with a 21-day interval in combination with standard of care (pembrolizumab 200 mg Q3 weeks or 400 mg Q6 weeks and capecitabine as per FDA approved label and currently accepted guidelines).
Following SRC review of the safety lead-in participants, an expansion cohort of up to 17 additional participants will be enrolled in both Cohorts 1B and 2B, bringing Part B to a total of up to 40 participants (up to 20 participants per cohort).
After all Part B participants have completed the Follow-up #1 visit, the SRC will meet to guide further clinical development of ITI-5000. The final analysis will take place after the end of the study.
In both Part A and Part B, participants will undergo 3 main study periods: a screening period, a treatment period (also named study vaccination period) with 3 study visits during which each participant will receive a total of 3 ITI-5000 vaccinations: 28 days
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Being tested
- ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib, Capecitabine, ITI-5000 MTD (Maximum Tolerated Dose)
- Keywords
- TNBC, saRNA, Pembrolizumab, Phase I Clinical Trial, Immunotherapy, HERV-K, First in Human (FIH), CT83
- Medical subject headings
- Triple Negative Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ITI-5000 mRNA VaccineBiological
Participants receive ITI-5000. Cohort 1 will receive 1 ug of vaccine
PembrolizumabDrug
Participants will receive ITI-5000 as an intramuscular injection every 21 days for 3 doses. Participants will also receive pembrolizumab as per the FDA-approved package insert.
ITI-5000 mRNA VaccineBiological
Participants receive ITI-5000. Cohort 2 will receive 10 ug of vaccine
OlaparibDrug
Participants will receive Olaparib in combination with Pembrolizumab and ITI-5000
CapecitabineDrug
Participants will receive Capecitabine in combination with Pembrolizumab and ITI-5000
ITI-5000 MTD (Maximum Tolerated Dose)Biological
Participants receive ITI-5000 Maximum Tolerated Dose (MTD)
| Study group | Role | What they receive |
|---|---|---|
| Part A, Cohort 1 ITI-5000 1 µg Monotherapy | Experimental | Participants receive ITI-5000 1 µg as an intramuscular injection every 28 days for 3 doses. Receives: Biological: ITI-5000 mRNA Vaccine |
| Part A, Cohort 2 ITI-5000 10 µg Monotherapy | Experimental | Participants receive ITI-5000 10 µg as an intramuscular injection every 28 days for 3 doses. Receives: Biological: ITI-5000 mRNA Vaccine |
| Part B ITI-5000 and Pembrolizumab + Olaparib | Experimental | Participants receive ITI-5000 at the dose determined in Part A as an injection every 21 days for 3 doses. Participants will also receive pembrolizumab 200 mg or 400 mg per FDA-approved package insert plus Olaparib. Receives: Drug: Pembrolizumab; Drug: Olaparib; Biological: ITI-5000 MTD (Maximum Tolerated Dose) |
| Part A, Cohort 3 ITI-5000 Monotherapy Expansion | Experimental | Participants receive ITI-5000 Maximum Tolerated Dose (MTD) as an intramuscular injection every 28 days for three doses Receives: Biological: ITI-5000 MTD (Maximum Tolerated Dose) |
| Part B ITI-5000 and Pembrolizumab+Capecitabine | Experimental | Participants receive ITI-5000 at the dose determined in Part A as an injection every 21 days for three doses. Participants also receive Pembrolizumab 200 mg or 400 mg per FDA-approved package insert plus Capecitabine Receives: Drug: Pembrolizumab; Drug: Capecitabine; Biological: ITI-5000 MTD (Maximum Tolerated Dose) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.0
Measured: 21-28 days after the first vaccination
Secondary outcomes (1)
Incidence and severity of TEAEs, SAEs, treatment-related TEAEs, AESIs, and clinically significant abnormalities in laboratory parameters, vital signs, and ECGs
Measured: From first dose through end of safety follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start14 Jul 2026
- Primary completionFeb 2028 (estimated)
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Triple Negative Breast Cancer (TNBC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This is a Phase 1, multicenter, open-label, parallel assignment clinical trial evaluating the safety, tolerability, and immunogenicity of ITI-5000, a self-amplifying RNA vaccine, administered alone or in combination with pembrolizumab plus either OIaparib or Capecitabine in adults with stage II-III triple-negative breast cancer (TNBC) who have completed standard curative-intent therapy; participants are assigned to either low- or high-dose ITI-5000 monotherapy cohorts (Part A) or to a combination therapy cohort with pembrolizumab at the maximum tolerated dose determined from Part A (Part B), with the primary objectives focused on dose-limiting toxicities and safety, and exploratory endpoints assessing immune response.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07652242
- Sponsor's protocol ID
- 5000-01-TNBC-P1
- Acronym
- VITAL-TNBC
- Status last verified
- Jul 2026
- First submitted
- 11 Jun 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Multicenter, Open-label, First-in-Human Study of ITI-5000 (Self-Amplifying RNA Vaccine) Alone and in Combination With Standard of Care Adjuvant Therapy in Participants With Stage II-III Triple-Negative Breast Cancer (TNBC)
- ClinicalTrials.gov ID
- NCT07652242
- Acronym / sponsor ID
- VITAL-TNBC / 5000-01-TNBC-P1
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Keywords
- TNBC, saRNA, Pembrolizumab, Phase I Clinical Trial, Immunotherapy, HERV-K, First in Human (FIH), CT83
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Immunomic Therapeutics, Inc.Industry (pharma, biotech, devices)
- Study start
- 14 Jul 2026 (actual)
- Primary completion
- Feb 2028 (estimated)
- Study completion
- Aug 2028 (estimated)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study tests an investigational cancer vaccine called ITI-5000 in people who have completed standard treatment for early-stage triple-negative breast cancer (TNBC).
ITI-5000 is a self-amplifying RNA (saRNA) vaccine that instructs the immune system to recognize and attack cancer cells expressing two proteins found on TNBC cells-HERV-K and CT83-fused with a molecule called LAMP-1 that helps the immune system respond more strongly. The vaccine is delivered inside lipid nanoparticles (LNPs), similar to other approved mRNA vaccines.
The study has two parts:
- Part A: Participants receive ITI-5000 alone at one of two dose levels (1 µg or 10 µg), given as an injection into the upper arm muscle every 28 days for 3 doses total. The goal is to find the safest dose.
- Part B: Participants receive ITI-5000 at the best dose identified in Part A, combined with the following approved immunotherapy drugs pembrolizumab (Keytruda) and either olaparib or capecitabine.
Detailed description
This will be a phase 1, FIH, multicenter, open-label, two-part, ascending dose study to evaluate the safety, tolerability, and immune response of the ITI-5000 vaccine in adult participants with TNBC (stage 2-3). The study will be divided into 2 parts: in Part A, participants will receive the ITI-5000 vaccine as a single agent in the post-adjuvant setting, and in Part B, participants will receive the ITI-5000 vaccine in combination with standard of care adjuvant therapy.
Part A will be divided into 2 dose level cohorts - Cohort 1A conducted at the dose of 1 μg (low dose) per vaccination and Cohort 2A conducted at the dose of 10 μg (high dose) per vaccination. In Part A, three vaccinations of ITI-5000 will be administered with a 28-day interval.
The first 3-6 participants will be enrolled sequentially, with the first participant designated as a sentinel participant who will be monitored for 28 days after receiving the first ITI-5000 vaccination before subsequent participants are enrolled. If 0/3 participants experience a DLT, Cohort 2A may proceed. If 1/3 of the participants experience a DLT, the cohort will expand to include 3 additional participants (total of 6). If ≥2/6 participants experience a DLT, the dose will be considered not tolerable, and the cohort will be stopped.
At the conclusion of each cohort, the safety review committee (SRC) will review safety signals and determine a rationale for dose escalation, de-escalation, or potential intermediate doses to be evaluated. The SRC will also determine the dose to be evaluated in Cohort 3A and Part B.
The MTD will be evaluated in Cohort 3A which will enroll up to 15 participants who did not achieve pathological complete response (pCR) following neoadjuvant therapy. This expansion will allow further assessment of safety and immunogenicity in a participant population that is at high risk of disease recurrence.
Part B will evaluate the MTD of ITI-5000 in combination with standard of care (SOC) adjuvant therapy among participants who did not achieve a pathological complete response (pCR) following neoadjuvant therapy.
A safety lead-in group comprising 3 participants will be enrolled at the beginning of Cohort 1B and 2B to assess the safety of the combination treatment. Unlike Part A, no sentinel participant will be required, as the safety of ITI-5000 alone will already have been established in Part A. The safety lead-in will provide an early evaluation of the tolerability of the combination regimen before enrolling additional participants.
Cohort 1B will enroll up to 20 participants with BRCA1/2 mutation who did not achieve pathological complete response (pCR) following neoadjuvant therapy. Three doses of ITI-5000 will be administered in the adjuvant setting with a 21-day interval in combination with standard of care (pembrolizumab 200 mg Q3 weeks or 400 mg Q6 weeks and olaparib as per FDA approved label and currently accepted guidelines).
Cohort 2B will enroll up to 20 participants with wild-type BRCA1/2 who did not achieve pCR following neoadjuvant therapy. Three doses of ITI-5000 will be administered in the adjuvant setting with a 21-day interval in combination with standard of care (pembrolizumab 200 mg Q3 weeks or 400 mg Q6 weeks and capecitabine as per FDA approved label and currently accepted guidelines).
Following SRC review of the safety lead-in participants, an expansion cohort of up to 17 additional participants will be enrolled in both Cohorts 1B and 2B, bringing Part B to a total of up to 40 participants (up to 20 participants per cohort).
After all Part B participants have completed the Follow-up #1 visit, the SRC will meet to guide further clinical development of ITI-5000. The final analysis will take place after the end of the study.
In both Part A and Part B, participants will undergo 3 main study periods: a screening period, a treatment period (also named study vaccination period) with 3 study visits during which each participant will receive a total of 3 ITI-5000 vaccinations: 28 days
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 5
- Model description
- This is a Phase 1, multicenter, open-label, parallel assignment clinical trial evaluating the safety, tolerability, and immunogenicity of ITI-5000, a self-amplifying RNA vaccine, administered alone or in combination with pembrolizumab plus either OIaparib or Capecitabine in adults with stage II-III triple-negative breast cancer (TNBC) who have completed standard curative-intent therapy; participants are assigned to either low- or high-dose ITI-5000 monotherapy cohorts (Part A) or to a combination therapy cohort with pembrolizumab at the maximum tolerated dose determined from Part A (Part B), with the primary objectives focused on dose-limiting toxicities and safety, and exploratory endpoints assessing immune response.
| Arm | Type | Receives |
|---|---|---|
| Part A, Cohort 1 ITI-5000 1 µg Monotherapy | Experimental | Biological: ITI-5000 mRNA VaccineParticipants receive ITI-5000 1 µg as an intramuscular injection every 28 days for 3 doses. |
| Part A, Cohort 2 ITI-5000 10 µg Monotherapy | Experimental | Biological: ITI-5000 mRNA VaccineParticipants receive ITI-5000 10 µg as an intramuscular injection every 28 days for 3 doses. |
| Part B ITI-5000 and Pembrolizumab + Olaparib | Experimental | Drug: Pembrolizumab, Drug: Olaparib, Biological: ITI-5000 MTD (Maximum Tolerated Dose)Participants receive ITI-5000 at the dose determined in Part A as an injection every 21 days for 3 doses. Participants will also receive pembrolizumab 200 mg or 400 mg per FDA-approved package insert plus Olaparib. |
| Part A, Cohort 3 ITI-5000 Monotherapy Expansion | Experimental | Biological: ITI-5000 MTD (Maximum Tolerated Dose)Participants receive ITI-5000 Maximum Tolerated Dose (MTD) as an intramuscular injection every 28 days for three doses |
| Part B ITI-5000 and Pembrolizumab+Capecitabine | Experimental | Drug: Pembrolizumab, Drug: Capecitabine, Biological: ITI-5000 MTD (Maximum Tolerated Dose)Participants receive ITI-5000 at the dose determined in Part A as an injection every 21 days for three doses. Participants also receive Pembrolizumab 200 mg or 400 mg per FDA-approved package insert plus Capecitabine |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (21 listed)
- Applicable to Part A only. Participants must have completed adjuvant pembrolizumab if they were receiving it before enrolling in the study.
- Applicable to Cohort 3A and Part B only. Participant must have received neoadjuvant chemotherapy with pembrolizumab, then undergone definitive surgery. At the time of surgery, participant must not have achieved pCR.
- Applicable to Part B only. Participant is currently receiving or is planned to receive standard of care adjuvant therapy, including pembrolizumab in combination with capecitabine or olaparib in accordance with the FDA-approved label, with ≥3 cycles remaining if receiving 200mg Q3W or ≥2 cycles remaining if receiving 400 mg Q6W at the time of first ITI-5000 dose.
- Adults aged 18 years or over.
- Participants provided a signed and dated ICF.
Key exclusion criteria (25 listed)
- Applicable to Part B only. Participant discontinued prior treatment with an ICI due to irAEs.
- Participant underwent major surgery within 4 weeks before the planned day of vaccination #1 or received any other investigational drug or device within 4 weeks or 5 half-lives of that agent (whichever is shorter) before the planned day of Vaccination #1.
- Participant has toxicities due to prior immunotherapy. For the participant to be eligible, these toxicities must either have returned to ≤ Grade 1 or baseline or been deemed irreversible and in the opinion of the investigator not worsened by immunotherapy (e.g., ICI-endocrinopathies). Participants with any cardiac toxicities (regardless of the grade, etc.) will be excluded.
- Participant has toxicities due to prior chemotherapy that have not been resolved or considered stable and clinically manageable (e.g., neuropathies). Participants with any cardiac toxicities will be excluded.
- Participant has a significant medical illness, underlying health condition, or abnormal laboratory finding that, in the investigator's opinion, would increase the risk of participating in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ITI-5000 mRNA VaccineParticipants receive ITI-5000. Cohort 1 will receive 1 ug of vaccine | Biological | Part A, Cohort 1 ITI-5000 1 µg Monotherapy |
| PembrolizumabParticipants will receive ITI-5000 as an intramuscular injection every 21 days for 3 doses. Participants will also receive pembrolizumab as per the FDA-approved package insert. | Drug | Part B ITI-5000 and Pembrolizumab + Olaparib, Part B ITI-5000 and Pembrolizumab+Capecitabine |
| ITI-5000 mRNA VaccineParticipants receive ITI-5000. Cohort 2 will receive 10 ug of vaccine | Biological | Part A, Cohort 2 ITI-5000 10 µg Monotherapy |
| OlaparibParticipants will receive Olaparib in combination with Pembrolizumab and ITI-5000 | Drug | Part B ITI-5000 and Pembrolizumab + Olaparib |
| CapecitabineParticipants will receive Capecitabine in combination with Pembrolizumab and ITI-5000 | Drug | Part B ITI-5000 and Pembrolizumab+Capecitabine |
| ITI-5000 MTD (Maximum Tolerated Dose)Participants receive ITI-5000 Maximum Tolerated Dose (MTD) | Biological | Part A, Cohort 3 ITI-5000 Monotherapy Expansion, Part B ITI-5000 and Pembrolizumab + Olaparib, Part B ITI-5000 and Pembrolizumab+Capecitabine |
Primary outcome
Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.0
Time frame: 21-28 days after the first vaccination
1 secondary outcome
Incidence and severity of TEAEs, SAEs, treatment-related TEAEs, AESIs, and clinically significant abnormalities in laboratory parameters, vital signs, and ECGs
Time frame: From first dose through end of safety follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Triple Negative Breast Cancer (TNBC)
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
RecruitingPhase 1/2
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Triple-Negative Breast Cancer (TNBC)
RecruitingPhase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ITI-5000 mRNA Vaccine, Pembrolizumab and Olaparib in people with Triple Negative Breast Cancer (TNBC), run by Immunomic Therapeutics, Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Scott L Wehage, M.S. (301-968-3501, studyinquiries@immunomix.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Dose-Limiting Toxicities as Assessed by CTCAE v5.0 (time frame: 21-28 days after the first vaccination). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.